Josée Thérèse Golay, PhD



Personal data:

Name:	Josée Thérèse Golay
Date and place of birth:	30/04/1959, Lausanne, Switzerland
Citizenship:	Swiss and Italian
Work address:	Laboratory of Cellular Therapy "G. Lanzani", Hematology Unit, A.O. Papa Giovanni XXIII c/o Presidio Matteo Rota via G. Garibaldi 11/13 24128 Bergamo, Italy
Phone:	+39 035 2278637
FAX:	+39 035 2278674
E-mail:	jgolay@hpg23.it

Education:

B.A. Honours degree in Biochemistry (upper second class) in 1983, Oxford University, England.
Ph.D.in 1986, Faculty of Medicine of University College, University of London, England.

Current position:

Senior Scientist, Laboratory of Cellular Therapy "G.Lanzani", Hematology Unit, A.O. Papa Giovanni XXIII, Bergamo, Italy
Lecturer/tutor within the DIMET Ph.D. Program in Translational and Molecular Medicine (DIMET), University of Milano-Bicocca,

Scientific activity:

Author of over 90 full per-reviewed international papers and 12 book chapters.

Principal investigator of Research Projects supported by: Associazione Italiana per la Ricerca sul Cancro (AIRC), Associazione Italiana contro La Leucemia, Linfoma e Mieloma (AIL), Ministero per la Università e la Ricerca Tecnologica (MIUR) and European Commission.
Member of the Antibody Society, USA, the American Association of Immunologists (AAI, USA), the Italian Society of Immunology, Clinical Immunology and Allergology (SIICA)(Italy)

Major scientific contributions in oncohematology:

- In 1984-5 first demonstration of the biological activity of antibodies directed against CD20, CD22 and CD19 in B cell proliferation and differentiation
- Demonstration of the role of complement in the mechanism of action of rituximab
- Demonstration of CD20 expression levels and complement inhibitors as mechanisms of resistance of leukemic cells to rituximab
- Demonstration of the role of chemokines and macrophages in the activity of rituximab in vitro ad in vivo
- Proposal of CD20 as a suicide gene in the context of graft versus host disease (patent)
- Proposals to combine antibody and cell therapy
- Development of a new bispecific antibody format (patent submitted)
- Demonstration of the role of ets1 in erythroid differentiation
- Identification of the A-myb oncogene as a marker of germinal center and not activated B cells
- Identification of the regulation and biological role of myb family oncogenes in hematopoietic
- cell proliferation and differentiation